T1	p 205 245	patients with atrial fibrillation ( AF )
T2	p 675 783	multinational ( 44 countries ) trial of patients with nonvalvular AF and at least 1 risk factor for stroke .
T3	p 822 922	18,113 patients . Patients who were VKA-naive and experienced are included in balanced proportions .
T4	i 63 105	long-term anticoagulant therapy , warfarin
T5	i 122 134	dabigatran .
T6	i 273 293	Dabigatran etexilate
T7	i 373 385	dabigatran .
T8	i 478 486	warfarin
T9	i 560 570	dabigatran
T10	i 1430 1440	dabigatran
T11	o 946 978	stroke ( including hemorrhagic )
T12	o 982 1001	systemic embolism .
T13	o 1022 1090	bleeding , liver function abnormalities , and other adverse events .